Wednesday, June 21, 2017 10:56:02 AM
In a statement, FDA Commissioner Scott Gottlieb, M.D. says the agency should do more to restrain high drug prices by facilitating more competition via approving lower-cost generic meds.
A public meeting is scheduled for July 18 to solicit input on areas the FDA should focus on to make it more straightforward for generic drug sponsors to get their products approved. Dr. Gottlieb's Drug Competition Action Plan will target agency rules, including standards and procedures, that may create obstacles to patient access to generics.
He cites examples of branded drug makers' behavior that impede the progress and encroachment of generic competition. For instance, they make it difficult for generic drug firms to acquire the amount of branded product needed for comparative testing.
Dr. Gottlieb adds that the FDA will explore ways to coordinate with the Federal Trade Commission in identifying and publicizing practices that the FTC deems anticompetitive.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM